Trial Search Results

Safety and Tolerability Study of SNS-314 for Advanced Solid Tumors

This is a study to assess the safety and tolerability of SNS-314 in advanced solid tumors in humans.

Stanford is currently not accepting patients for this trial.

Lead Sponsor:

Sunesis Pharmaceuticals

Stanford Investigator(s):


  • Drug: SNS-314


Phase 1


Inclusion Criteria:

   - Advanced solid tumor and that is measurable by a scan

Exclusion Criteria:

   - Uncontrolled or untreated central nervous system metastases

   - Cerebrovascular accident/transient ischemic attack up to 6 months before Cycle 1 Day 1

   - Any of the following cardiac conditions:

   - History of myocardial infarction, acute coronary syndromes up to 12 weeks before Cycle
   1 Day 1

   - Class III or IV heart failure up to 6 months before Cycle 1 Day 1

   - Baseline heart rate corrected QT interval (QTc)> 450 msec

   - History of ventricular arrhythmias up to 6 months before Cycle 1 Day 1

   - Use of medications that prolong the QTc interval and are associated with Torsades de
   Pointe (TdP)

   - Previous cancer treatment up to 21 days before first dose

   - Any investigational therapy up to 28 days before Cycle 1 Day 1

   - Known allergy to cyclodextrins

Please note: There are additional inclusion/exclusion criteria for this study. Please
contact the study center for additional information and to determine if all study criteria
are met.

Ages Eligible for Study

18 Years - N/A

Genders Eligible for Study